A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

A new multicenter study by researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with the National Cancer Institute-funded Clinical Proteomic Tumor Analysis Consortium (CPTAC) ...

Most cancer genome studies have focused on mutations in the tumor itself and how such gene variants allow a tumor to grow unchecked.

Most cancer genome studies have focused on mutations in the tumor itself and how such gene variants allow a tumor to grow unchecked. A new study takes a deep dive into inherited cancer mutations ...

In a nutshell Cambridge researchers developed a new DNA classification system that reveals hidden patterns in cancer, ...

A new multicenter study by researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and colleagues around the world, ...

Scientists have discovered a new weakness in lung cancer that could lead to better treatments and help prevent the disease ...

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

You will be redirected to our submission process. Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for the majority of ...

Researchers have discovered that 'DEAD-box helicases 54 (DDX54)', a type of RNA-binding protein, is the master regulator that hinders the effectiveness of immunotherapy -- opening a new path for lung ...

From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.

A gene once believed to be extremely rare may actually be surprisingly common—and capable of quietly raising the risk of ...